teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 146 Projects Releases Packages Wiki Activity Actions 236

auto-fix: strip 73 broken wiki links

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-04-14 16:47:25 +00:00
parent 883a880beb
commit 70255ac980
33 changed files with 73 additions and 73 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

2
domains/energy/arctic and nuclear-powered data centers solve the same power and cooling constraints as orbital compute without launch costs radiation or bandwidth limitations.md
View file

@ -47,4 +47,4 @@ Relevant Notes:
- [[space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density]] — the physics constraint giving terrestrial alternatives their advantage - [[space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density]] — the physics constraint giving terrestrial alternatives their advantage
Topics: Topics:
- [[space exploration and development]] - space exploration and development

4
domains/health/CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo.md
View file

@ -33,12 +33,12 @@ The investment implication: companies positioned at the category I boundary —
--- ---
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm]] | Added: 2026-03-31* *Source: 2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm | Added: 2026-03-31*
TEMPO + CMS ACCESS model formalizes a two-speed system at an earlier stage: pre-clearance devices get Medicare reimbursement through ACCESS while collecting evidence, versus cleared devices with standard coverage. This creates a research-to-reimbursement pathway that didn't exist before January 2026, but scale is limited to ~10 manufacturers per clinical area. TEMPO + CMS ACCESS model formalizes a two-speed system at an earlier stage: pre-clearance devices get Medicare reimbursement through ACCESS while collecting evidence, versus cleared devices with standard coverage. This creates a research-to-reimbursement pathway that didn't exist before January 2026, but scale is limited to ~10 manufacturers per clinical area.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period]] | Added: 2026-04-01* *Source: 2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period | Added: 2026-04-01*
TEMPO + ACCESS coordination demonstrates the two-speed system in practice: Medicare beneficiaries (65+) gain access to FDA-approved digital health devices through TEMPO while Medicaid populations face coverage contraction. The ACCESS model's July 1, 2026 performance period start creates a defined timeline for when Medicare digital health infrastructure becomes operational, while no equivalent pathway exists for Medicaid populations. TEMPO + ACCESS coordination demonstrates the two-speed system in practice: Medicare beneficiaries (65+) gain access to FDA-approved digital health devices through TEMPO while Medicaid populations face coverage contraction. The ACCESS model's July 1, 2026 performance period start creates a defined timeline for when Medicare digital health infrastructure becomes operational, while no equivalent pathway exists for Medicaid populations.

8
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -144,24 +144,24 @@ Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded an
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20* *Source: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics | Added: 2026-03-20*
India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033. India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033.
--- ---
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-03-21-natco-semaglutide-india-day1-launch-1290]] | Added: 2026-03-21* *Source: 2026-03-21-natco-semaglutide-india-day1-launch-1290 | Added: 2026-03-21*
Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on March 20, 2026, the day the patent expired. This is 90% below innovator pricing and 2-3x lower than analyst projections made days earlier ($40-77/month within a year). 50+ manufacturers from 40+ companies are entering the market, with Sun Pharma, Zydus, Dr. Reddy's, and Eris launching on Day 1. The 'inflationary through 2035' timeline is empirically wrong for international markets—price compression is happening in 2026, not 2030+. Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on March 20, 2026, the day the patent expired. This is 90% below innovator pricing and 2-3x lower than analyst projections made days earlier ($40-77/month within a year). 50+ manufacturers from 40+ companies are entering the market, with Sun Pharma, Zydus, Dr. Reddy's, and Eris launching on Day 1. The 'inflationary through 2035' timeline is empirically wrong for international markets—price compression is happening in 2026, not 2030+.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-21-semaglutide-us-import-wall-gray-market-pressure]] | Added: 2026-03-21* *Source: 2026-03-21-semaglutide-us-import-wall-gray-market-pressure | Added: 2026-03-21*
US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale. US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale.
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-03-22-health-canada-rejects-dr-reddys-semaglutide]] | Added: 2026-03-22* *Source: 2026-03-22-health-canada-rejects-dr-reddys-semaglutide | Added: 2026-03-22*
Health Canada rejected Dr. Reddy's generic semaglutide application in October 2025, delaying Canada launch to 2027 at earliest (8-12 month review cycle after resubmission). This contradicts the Session 9 projection of May 2026 Canada launch and reveals regulatory friction as a significant barrier to generic GLP-1 market entry. Canada's patents expired January 2026, but regulatory approval does not automatically follow patent expiration. The delay removes the primary high-income market data point for 2026, leaving only India's $15-55/month pricing as the sole confirmed generic market reference. Canada was expected to establish pricing floors for high-income markets with US-comparable health infrastructure, but that calibration point is now delayed 12+ months beyond patent cliff. Health Canada rejected Dr. Reddy's generic semaglutide application in October 2025, delaying Canada launch to 2027 at earliest (8-12 month review cycle after resubmission). This contradicts the Session 9 projection of May 2026 Canada launch and reveals regulatory friction as a significant barrier to generic GLP-1 market entry. Canada's patents expired January 2026, but regulatory approval does not automatically follow patent expiration. The delay removes the primary high-income market data point for 2026, leaving only India's $15-55/month pricing as the sole confirmed generic market reference. Canada was expected to establish pricing floors for high-income markets with US-comparable health infrastructure, but that calibration point is now delayed 12+ months beyond patent cliff.

4
domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
View file

@ -71,13 +71,13 @@ Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* *Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-18*
Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented. Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19* *Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19*
Aon's 192,000+ patient analysis adds cancer risk reduction to the multi-organ benefit profile: female GLP-1 users showed ~50% lower ovarian cancer incidence and 14% lower breast cancer incidence. Also associated with lower rates of osteoporosis, rheumatoid arthritis, and fewer hospitalizations for alcohol/drug abuse and bariatric surgery. The sex-differential in MACE reduction (47% for women vs 26% for men) suggests benefits may be larger for women, which has implications for risk adjustment in Medicare Advantage. Aon's 192,000+ patient analysis adds cancer risk reduction to the multi-organ benefit profile: female GLP-1 users showed ~50% lower ovarian cancer incidence and 14% lower breast cancer incidence. Also associated with lower rates of osteoporosis, rheumatoid arthritis, and fewer hospitalizations for alcohol/drug abuse and bariatric surgery. The sex-differential in MACE reduction (47% for women vs 26% for men) suggests benefits may be larger for women, which has implications for risk adjustment in Medicare Advantage.

2
domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
View file

@ -120,7 +120,7 @@ Aon data shows benefits scale dramatically with adherence: for diabetes patients
Novo Nordisk's response to India's generic launch reveals market expansion strategy: only 200,000 of 250 million obese Indians are currently on GLP-1s. The company is competing on 'market expansion over price war,' suggesting the primary barrier is access/awareness, not price sensitivity. This implies persistence challenges may be access-driven in international markets rather than purely adherence-driven. Novo Nordisk's response to India's generic launch reveals market expansion strategy: only 200,000 of 250 million obese Indians are currently on GLP-1s. The company is competing on 'market expansion over price war,' suggesting the primary barrier is access/awareness, not price sensitivity. This implies persistence challenges may be access-driven in international markets rather than purely adherence-driven.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2025-04-01-jmir-glp1-digital-engagement-outcomes-retrospective]] | Added: 2026-03-24* *Source: 2025-04-01-jmir-glp1-digital-engagement-outcomes-retrospective | Added: 2026-03-24*
US real-world data from JMIR 2025 shows digital engagement produces 11.53% weight loss vs. 8% for non-engaged participants at month 5 (3.5pp advantage). Study covers both semaglutide and tirzepatide, demonstrating the behavioral support effect generalizes across GLP-1/GIP receptor agonists. When supply and coverage issues are addressed, persistence improves to 63%, suggesting the adherence gap is partially addressable through digital platform integration (live coaching, monitoring, education). US real-world data from JMIR 2025 shows digital engagement produces 11.53% weight loss vs. 8% for non-engaged participants at month 5 (3.5pp advantage). Study covers both semaglutide and tirzepatide, demonstrating the behavioral support effect generalizes across GLP-1/GIP receptor agonists. When supply and coverage issues are addressed, persistence improves to 63%, suggesting the adherence gap is partially addressable through digital platform integration (live coaching, monitoring, education).

4
domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md
View file

@ -33,12 +33,12 @@ This provides the strongest single empirical case for the claim that medical car
--- ---
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2024-xx-ajpm-cvd-mortality-trends-2010-2022-update-final-data]] | Added: 2026-03-31* *Source: 2024-xx-ajpm-cvd-mortality-trends-2010-2022-update-final-data | Added: 2026-03-31*
US CVD age-adjusted mortality rate in 2022 returned to 2012 levels (434.6 per 100,000 for adults ≥35), erasing a decade of progress. Adults aged 35-54 experienced elimination of the preceding decade's CVD gains from 2019-2022, with 228,524 excess CVD deaths 2020-2022 (9% above expected). The midlife pattern is inconsistent with COVID harvesting (which primarily affects the frail elderly) and suggests structural disease load. US CVD age-adjusted mortality rate in 2022 returned to 2012 levels (434.6 per 100,000 for adults ≥35), erasing a decade of progress. Adults aged 35-54 experienced elimination of the preceding decade's CVD gains from 2019-2022, with 228,524 excess CVD deaths 2020-2022 (9% above expected). The midlife pattern is inconsistent with COVID harvesting (which primarily affects the frail elderly) and suggests structural disease load.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2024-06-xx-aha-hypertension-sdoh-systematic-review-57-studies]] | Added: 2026-03-31* *Source: 2024-06-xx-aha-hypertension-sdoh-systematic-review-57-studies | Added: 2026-03-31*
Systematic review of 57 studies identifies the specific SDOH mechanisms: food insecurity, unemployment, poverty-level income, low education, and inadequate insurance independently predict hypertension prevalence and poor BP control. The review explicitly states that 'multilevel collaboration and community-engaged practices are necessary to reduce hypertension disparities — siloed clinical or technology interventions are insufficient.' Systematic review of 57 studies identifies the specific SDOH mechanisms: food insecurity, unemployment, poverty-level income, low education, and inadequate insurance independently predict hypertension prevalence and poor BP control. The review explicitly states that 'multilevel collaboration and community-engaged practices are necessary to reduce hypertension disparities — siloed clinical or technology interventions are insufficient.'

2
domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md
View file

@ -21,6 +21,6 @@ reweave_edges:
The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAMR) doubled from 15.8 per 100,000 (1999) to 31.9 (2023), making it 'the fastest rising underlying cause of cardiovascular death.' Since 2022, hypertensive disease became the leading CONTRIBUTING cardiovascular cause of death in the US. The mechanism is structural: obesity prevalence, sedentary behavior, and metabolic syndrome create a treatment-resistant hypertension burden that pharmacological interventions (ACE inhibitors, ARBs, diuretics) can manage but not eliminate. The geographic and demographic pattern confirms this: increases are disproportionate in Southern states (higher baseline obesity, lower healthcare access), Black Americans (structural hypertension treatment gap), and rural vs. urban areas. This represents a fundamental divergence from ischemic heart disease, which declined over the same period due to acute care improvements (stenting, statins). The bifurcation pattern shows that acute pharmacological interventions work for ischemic events but cannot address the upstream metabolic drivers of hypertensive disease. The doubling occurred despite widespread availability of effective antihypertensive medications, indicating the problem is behavioral and structural, not pharmaceutical. The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAMR) doubled from 15.8 per 100,000 (1999) to 31.9 (2023), making it 'the fastest rising underlying cause of cardiovascular death.' Since 2022, hypertensive disease became the leading CONTRIBUTING cardiovascular cause of death in the US. The mechanism is structural: obesity prevalence, sedentary behavior, and metabolic syndrome create a treatment-resistant hypertension burden that pharmacological interventions (ACE inhibitors, ARBs, diuretics) can manage but not eliminate. The geographic and demographic pattern confirms this: increases are disproportionate in Southern states (higher baseline obesity, lower healthcare access), Black Americans (structural hypertension treatment gap), and rural vs. urban areas. This represents a fundamental divergence from ischemic heart disease, which declined over the same period due to acute care improvements (stenting, statins). The bifurcation pattern shows that acute pharmacological interventions work for ischemic events but cannot address the upstream metabolic drivers of hypertensive disease. The doubling occurred despite widespread availability of effective antihypertensive medications, indicating the problem is behavioral and structural, not pharmaceutical.
### Additional Evidence (confirm) ### Additional Evidence (confirm)
*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03* *Source: 2026-01-21-aha-2026-heart-disease-stroke-statistics-update | Added: 2026-04-03*
AHA 2026 statistics confirm hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 (1999-2023) and became the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This is the definitive annual data source confirming the trend. AHA 2026 statistics confirm hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 (1999-2023) and became the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This is the definitive annual data source confirming the trend.

2
domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md
View file

@ -71,7 +71,7 @@ OBBBA work requirements threaten to remove ~10M from Medicaid coverage precisely
--- ---
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021]] | Added: 2026-03-29* *Source: 2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021 | Added: 2026-03-29*
PCSK9 inhibitors show sociodemographic disparities in utilization independent of clinical indication. JAHA 2021 adoption study found Black and Hispanic ASCVD patients had lower PCSK9 utilization than white patients at all income levels. This pattern parallels GLP-1 discontinuation disparities, suggesting affordability/access barriers create systematic underutilization in lower-income and minority populations across multiple high-cost cardiovascular/metabolic drug classes. PCSK9 inhibitors show sociodemographic disparities in utilization independent of clinical indication. JAHA 2021 adoption study found Black and Hispanic ASCVD patients had lower PCSK9 utilization than white patients at all income levels. This pattern parallels GLP-1 discontinuation disparities, suggesting affordability/access barriers create systematic underutilization in lower-income and minority populations across multiple high-cost cardiovascular/metabolic drug classes.

2
domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md
View file

@ -80,7 +80,7 @@ Amodei's complementary factors framework explicitly identifies 'human constraint
PNAS 2026 attributes US life expectancy stagnation to 'a complex convergence of rising chronic disease, shifting behavioral risks, and increases in certain cancers among younger adults' — explicitly identifying behavioral and social factors as the drivers of cohort-level mortality deterioration, not medical care quality. PNAS 2026 attributes US life expectancy stagnation to 'a complex convergence of rising chronic disease, shifting behavioral risks, and increases in certain cancers among younger adults' — explicitly identifying behavioral and social factors as the drivers of cohort-level mortality deterioration, not medical care quality.
### Additional Evidence (confirm) ### Additional Evidence (confirm)
*Source: [[2026-03-30-jacc-cvd-mortality-trends-1999-2023]] | Added: 2026-03-30* *Source: 2026-03-30-jacc-cvd-mortality-trends-1999-2023 | Added: 2026-03-30*
Hypertension-related CVD mortality doubled 2000-2023 (23→43 per 100,000) despite widespread availability of effective, cheap generic antihypertensives. This is the strongest single empirical case for the 80-90% non-clinical determinants thesis because the failure occurs despite pharmacological solutions being universally accessible, proving the constraint is behavioral/SDOH not medical. Hypertension-related CVD mortality doubled 2000-2023 (23→43 per 100,000) despite widespread availability of effective, cheap generic antihypertensives. This is the strongest single empirical case for the 80-90% non-clinical determinants thesis because the failure occurs despite pharmacological solutions being universally accessible, proving the constraint is behavioral/SDOH not medical.

2
domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md
View file

@ -49,7 +49,7 @@ SELECT trial economic model shows $2,074 per-subject lifetime savings from avoid
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18* *Source: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics | Added: 2026-03-18*
In the Medicare comprehensive model, CKD-related savings contribute $2,074 per subject treated, which is smaller than T2D savings ($14,431/subject) but still material. The 10-year modeling window may underestimate dialysis delay value since ESRD costs accumulate over longer periods. MASH savings were only $28M system-wide, suggesting treatment costs don't accumulate enough in the 10-year window to produce large offsets despite clinical efficacy. In the Medicare comprehensive model, CKD-related savings contribute $2,074 per subject treated, which is smaller than T2D savings ($14,431/subject) but still material. The 10-year modeling window may underestimate dialysis delay value since ESRD costs accumulate over longer periods. MASH savings were only $28M system-wide, suggesting treatment costs don't accumulate enough in the 10-year window to produce large offsets despite clinical efficacy.

2
domains/health/the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification.md
View file

@ -22,7 +22,7 @@ This two-track system has structural implications. It lowers the barrier for get
--- ---
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm]] | Added: 2026-03-31* *Source: 2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm | Added: 2026-03-31*
TEMPO pilot creates the next layer of FDA digital health deregulation beyond the January 2026 CDS guidance: enforcement discretion for uncleared devices deployed in real-world Medicare settings. This is a structured pathway for collecting the outcomes data that traditional FDA review requires, creating a workaround for the regulatory pathway problem where companies need data to get clearance but need clearance to collect data at scale. TEMPO pilot creates the next layer of FDA digital health deregulation beyond the January 2026 CDS guidance: enforcement discretion for uncleared devices deployed in real-world Medicare settings. This is a structured pathway for collecting the outcomes data that traditional FDA review requires, creating a workaround for the regulatory pathway problem where companies need data to get clearance but need clearance to collect data at scale.

4
domains/health/the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md
View file

@ -31,13 +31,13 @@ Since specialization and value form an autocatalytic feedback loop where each am
### Additional Evidence (confirm) ### Additional Evidence (confirm)
*Source: [[2024-09-19-commonwealth-fund-mirror-mirror-2024]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5* *Source: 2024-09-19-commonwealth-fund-mirror-mirror-2024 | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
The Commonwealth Fund's 2024 international comparison demonstrates this transition empirically across 10 developed nations. All countries compared (Australia, Canada, France, Germany, Netherlands, New Zealand, Sweden, Switzerland, UK, US) have eliminated material scarcity in healthcare — all possess advanced clinical capabilities and universal or near-universal access infrastructure. Yet health outcomes vary dramatically. The US spends >16% of GDP (highest by far) with worst outcomes, while top performers (Australia, Netherlands) spend the lowest percentage of GDP. The differentiator is not clinical capability (US ranks 2nd in care process quality) but access structures and equity — social determinants. This proves that among developed nations with sufficient material resources, social disadvantage (who gets care, discrimination, equity barriers) drives outcomes more powerfully than clinical quality or spending volume. The Commonwealth Fund's 2024 international comparison demonstrates this transition empirically across 10 developed nations. All countries compared (Australia, Canada, France, Germany, Netherlands, New Zealand, Sweden, Switzerland, UK, US) have eliminated material scarcity in healthcare — all possess advanced clinical capabilities and universal or near-universal access infrastructure. Yet health outcomes vary dramatically. The US spends >16% of GDP (highest by far) with worst outcomes, while top performers (Australia, Netherlands) spend the lowest percentage of GDP. The differentiator is not clinical capability (US ranks 2nd in care process quality) but access structures and equity — social determinants. This proves that among developed nations with sufficient material resources, social disadvantage (who gets care, discrimination, equity barriers) drives outcomes more powerfully than clinical quality or spending volume.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15* *Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15*
GLP-1 access inequality demonstrates the epidemiological transition in action: the intervention addresses metabolic disease (post-transition health problem) but access stratifies by wealth and insurance status (social disadvantage), potentially widening health inequalities even as population-level outcomes improve. The WHO's emphasis on 'multisectoral action' and 'healthier environments' acknowledges that pharmaceutical solutions alone cannot address socially-determined health outcomes. GLP-1 access inequality demonstrates the epidemiological transition in action: the intervention addresses metabolic disease (post-transition health problem) but access stratifies by wealth and insurance status (social disadvantage), potentially widening health inequalities even as population-level outcomes improve. The WHO's emphasis on 'multisectoral action' and 'healthier environments' acknowledges that pharmaceutical solutions alone cannot address socially-determined health outcomes.

2
domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md
View file

@ -21,6 +21,6 @@ reweave_edges:
The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structural reversal over 12 years. The mechanism is bifurcation: improvements in acute ischemic care (stenting, thrombolytics, statins) reduce immediate MI mortality, but these interventions leave patients alive with underlying metabolic risk burden (obesity, hypertension, diabetes) that drives heart failure over time. Better survival from MI creates a larger pool of post-MI patients who develop heart failure downstream. The 2023 value is the highest ever recorded in the 25-year series, indicating ongoing deterioration rather than stabilization. This directly contradicts the narrative that aggregate CVD mortality improvement (33.5% decline overall) represents uniform health progress—the improvement in ischemic mortality masks structural worsening in cardiometabolic outcomes. The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structural reversal over 12 years. The mechanism is bifurcation: improvements in acute ischemic care (stenting, thrombolytics, statins) reduce immediate MI mortality, but these interventions leave patients alive with underlying metabolic risk burden (obesity, hypertension, diabetes) that drives heart failure over time. Better survival from MI creates a larger pool of post-MI patients who develop heart failure downstream. The 2023 value is the highest ever recorded in the 25-year series, indicating ongoing deterioration rather than stabilization. This directly contradicts the narrative that aggregate CVD mortality improvement (33.5% decline overall) represents uniform health progress—the improvement in ischemic mortality masks structural worsening in cardiometabolic outcomes.
### Additional Evidence (confirm) ### Additional Evidence (confirm)
*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03* *Source: 2026-01-21-aha-2026-heart-disease-stroke-statistics-update | Added: 2026-04-03*
2023 data shows heart failure mortality at 21.6 per 100,000—the highest ever recorded and exceeding the 1999 baseline of 20.3. After declining to 16.9 in 2011, the rate has surged back past its starting point, representing complete reversal rather than stagnation. 2023 data shows heart failure mortality at 21.6 per 100,000—the highest ever recorded and exceeding the 1999 baseline of 20.3. After declining to 16.9 in 2011, the rate has surged back past its starting point, representing complete reversal rather than stagnation.

8
domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md
View file

@ -57,25 +57,25 @@ The BALANCE Model moves payment toward genuine risk by adjusting capitated rates
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16* *Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16*
CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by implementing capitation adjustment (paying plans MORE for obesity coverage) plus reinsurance (removing tail risk) rather than expecting prevention incentives to emerge from capitation alone. This is explicit structural redesign around the identified barriers. CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by implementing capitation adjustment (paying plans MORE for obesity coverage) plus reinsurance (removing tail risk) rather than expecting prevention incentives to emerge from capitation alone. This is explicit structural redesign around the identified barriers.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2025-01-01-nashp-chw-state-policies-2024-2025]] | Added: 2026-03-18* *Source: 2025-01-01-nashp-chw-state-policies-2024-2025 | Added: 2026-03-18*
CHW reimbursement infrastructure demonstrates the same payment boundary stall in the SDOH domain: 20 states with approved SPAs after 17 years, with billing code uptake remaining slow even where reimbursement is technically available. The bottleneck is not policy approval but operational infrastructure — CBOs cannot contract with healthcare entities, transportation costs are not covered, and 'community care hubs' are emerging as coordination infrastructure. This parallels VBC's 60% touch / 14% risk gap: technical capability exists but the operational infrastructure to execute at scale does not. CHW reimbursement infrastructure demonstrates the same payment boundary stall in the SDOH domain: 20 states with approved SPAs after 17 years, with billing code uptake remaining slow even where reimbursement is technically available. The bottleneck is not policy approval but operational infrastructure — CBOs cannot contract with healthcare entities, transportation costs are not covered, and 'community care hubs' are emerging as coordination infrastructure. This parallels VBC's 60% touch / 14% risk gap: technical capability exists but the operational infrastructure to execute at scale does not.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-20-fierce-healthcare-obbba-domino-effect]] | Added: 2026-03-20* *Source: 2026-03-20-fierce-healthcare-obbba-domino-effect | Added: 2026-03-20*
Fierce Healthcare's 2026 outlook shows the OBBBA domino mechanism: Medicaid work requirements → coverage loss → newly uninsured seek ER care → uncompensated care absorbed by health systems → financial stress → less investment in VBC infrastructure → VBC transition slows. This provides a specific causal pathway for how policy-induced coverage disruption directly undermines VBC adoption by forcing health systems to absorb uncompensated care costs that would otherwise fund infrastructure investment. Fierce Healthcare's 2026 outlook shows the OBBBA domino mechanism: Medicaid work requirements → coverage loss → newly uninsured seek ER care → uncompensated care absorbed by health systems → financial stress → less investment in VBC infrastructure → VBC transition slows. This provides a specific causal pathway for how policy-induced coverage disruption directly undermines VBC adoption by forcing health systems to absorb uncompensated care costs that would otherwise fund infrastructure investment.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-20-obbba-vbc-enrollment-stability-mechanism]] | Added: 2026-03-20* *Source: 2026-03-20-obbba-vbc-enrollment-stability-mechanism | Added: 2026-03-20*
VBC transitions face a second stall mechanism beyond the payment boundary: population stability. OBBBA's work requirements and semi-annual redeterminations fragment continuous enrollment, preventing VBC plans from capturing prevention investment payback even when payment models are correctly structured. CHW programs with 12-18 month payback periods fail when members churn before savings realize. This is a structural barrier independent of risk-bearing levels. VBC transitions face a second stall mechanism beyond the payment boundary: population stability. OBBBA's work requirements and semi-annual redeterminations fragment continuous enrollment, preventing VBC plans from capturing prevention investment payback even when payment models are correctly structured. CHW programs with 12-18 month payback periods fail when members churn before savings realize. This is a structural barrier independent of risk-bearing levels.

2
domains/space-development/Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors.md
View file

@ -41,4 +41,4 @@ Relevant Notes:
- [[the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit]] — Axiom's financial difficulties are the single largest risk factor for the gap scenario - [[the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit]] — Axiom's financial difficulties are the single largest risk factor for the gap scenario
Topics: Topics:
- [[space exploration and development]] - space exploration and development

2
domains/space-development/Blue Origin cislunar infrastructure strategy mirrors AWS by building comprehensive platform layers while competitors optimize individual services.md
View file

@ -30,7 +30,7 @@ The key risk is historically slow execution and total Bezos dependency. Two succ
--- ---
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-03-28-nasaspaceflight-new-glenn-manufacturing-odc-ambitions]] | Added: 2026-03-28* *Source: 2026-03-28-nasaspaceflight-new-glenn-manufacturing-odc-ambitions | Added: 2026-03-28*
Blue Origin's Project Sunrise ambitions (51,600 orbital data center satellites) require Starlink-like launch cadence, but actual New Glenn operations show 1.6 launches/year versus 12/year manufacturing capacity. The AWS-mirroring strategy assumes operational execution will scale with manufacturing, but 15 months of New Glenn operations reveal a 6-8x execution gap that makes the comprehensive platform buildout timeline implausible. Blue Origin's Project Sunrise ambitions (51,600 orbital data center satellites) require Starlink-like launch cadence, but actual New Glenn operations show 1.6 launches/year versus 12/year manufacturing capacity. The AWS-mirroring strategy assumes operational execution will scale with manufacturing, but 15 months of New Glenn operations reveal a 6-8x execution gap that makes the comprehensive platform buildout timeline implausible.

12
domains/space-development/SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal.md
View file

@ -27,37 +27,37 @@ The question for the space industry is not whether SpaceX will be dominant but w
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-03-18-blue-origin-ng3-booster-reuse]] | Added: 2026-03-18* *Source: 2026-03-18-blue-origin-ng3-booster-reuse | Added: 2026-03-18*
Blue Origin's patient capital model ($14B+ Bezos investment) produced a second operational reusable heavy-lift provider with successful booster landing on only 2nd orbital attempt (NG-2) and first reuse attempt at ~3 month turnaround (NG-3). The booster is designed for 25+ flights, approaching Falcon 9's operational reuse economics. This demonstrates that sustained capital investment without revenue pressure can produce competitive reusable launch capability, challenging the necessity of SpaceX's specific vertical integration model. Blue Origin's patient capital model ($14B+ Bezos investment) produced a second operational reusable heavy-lift provider with successful booster landing on only 2nd orbital attempt (NG-2) and first reuse attempt at ~3 month turnaround (NG-3). The booster is designed for 25+ flights, approaching Falcon 9's operational reuse economics. This demonstrates that sustained capital investment without revenue pressure can produce competitive reusable launch capability, challenging the necessity of SpaceX's specific vertical integration model.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-18-varda-w5-vertically-integrated-bus]] | Added: 2026-03-18* *Source: 2026-03-18-varda-w5-vertically-integrated-bus | Added: 2026-03-18*
Varda's vertical integration milestone (own bus + own heatshield) demonstrates the pattern extends beyond launch to space manufacturing. The C-PICA heatshield manufactured in-house at El Segundo enables faster iteration cycles and cost reduction through the same flywheel mechanism SpaceX uses for Falcon 9. Varda's vertical integration milestone (own bus + own heatshield) demonstrates the pattern extends beyond launch to space manufacturing. The C-PICA heatshield manufactured in-house at El Segundo enables faster iteration cycles and cost reduction through the same flywheel mechanism SpaceX uses for Falcon 9.
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-03-18-new-glenn-ng3-booster-reuse-pending]] | Added: 2026-03-18* *Source: 2026-03-18-new-glenn-ng3-booster-reuse-pending | Added: 2026-03-18*
Blue Origin achieved booster landing on only their 2nd attempt (NG-2, Nov 2025) and is now demonstrating reuse on NG-3 with a 3-month turnaround. This suggests non-SpaceX players can achieve operational reuse cadence faster than SpaceX's historical learning curve, challenging the claim that SpaceX's advantages are unreplicable. However, the 3-month turnaround is still 3-6x slower than SpaceX's mature operations, so the competitive moat may be in optimization speed rather than capability access. Blue Origin achieved booster landing on only their 2nd attempt (NG-2, Nov 2025) and is now demonstrating reuse on NG-3 with a 3-month turnaround. This suggests non-SpaceX players can achieve operational reuse cadence faster than SpaceX's historical learning curve, challenging the claim that SpaceX's advantages are unreplicable. However, the 3-month turnaround is still 3-6x slower than SpaceX's mature operations, so the competitive moat may be in optimization speed rather than capability access.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-00-commercial-stations-haven1-slip-orbital-reef-delays]] | Added: 2026-03-19* *Source: 2026-03-00-commercial-stations-haven1-slip-orbital-reef-delays | Added: 2026-03-19*
Orbital Reef's multi-party structure (Blue Origin, Sierra Space, Boeing) appears to be creating coordination delays and funding allocation challenges, contrasting with vertically integrated approaches. Blue Origin's capital allocation across New Shepard, New Glenn, BE-4 engines, and Orbital Reef simultaneously may be straining even Bezos's 'patient capital' model—the first signal that Blue Origin's multi-program strategy faces resource constraints. This suggests vertical integration advantages extend beyond technical efficiency to capital allocation coherence. Orbital Reef's multi-party structure (Blue Origin, Sierra Space, Boeing) appears to be creating coordination delays and funding allocation challenges, contrasting with vertically integrated approaches. Blue Origin's capital allocation across New Shepard, New Glenn, BE-4 engines, and Orbital Reef simultaneously may be straining even Bezos's 'patient capital' model—the first signal that Blue Origin's multi-program strategy faces resource constraints. This suggests vertical integration advantages extend beyond technical efficiency to capital allocation coherence.
--- ---
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2025-12-10-cnbc-starcloud-first-llm-trained-space-h100]] | Added: 2026-03-24* *Source: 2025-12-10-cnbc-starcloud-first-llm-trained-space-h100 | Added: 2026-03-24*
Starcloud's use of SpaceX rideshare to bootstrap orbital AI compute, combined with NVIDIA's strategic backing (GPU manufacturer + compute operator relationship), suggests a similar vertical-integration pattern emerging in the orbital data center sector. NVIDIA's Space Computing initiative and commitment to deploy Blackwell platforms by October 2026 creates a semiconductor-platform-vendor-to-orbital-operator relationship analogous to SpaceX's launch-to-Starlink integration. This may indicate that vertical integration advantages compound across different space industry segments, not just within SpaceX's specific stack. Starcloud's use of SpaceX rideshare to bootstrap orbital AI compute, combined with NVIDIA's strategic backing (GPU manufacturer + compute operator relationship), suggests a similar vertical-integration pattern emerging in the orbital data center sector. NVIDIA's Space Computing initiative and commitment to deploy Blackwell platforms by October 2026 creates a semiconductor-platform-vendor-to-orbital-operator relationship analogous to SpaceX's launch-to-Starlink integration. This may indicate that vertical integration advantages compound across different space industry segments, not just within SpaceX's specific stack.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-27-blueorigin-new-glenn-manufacturing-odc-ambitions]] | Added: 2026-03-27* *Source: 2026-03-27-blueorigin-new-glenn-manufacturing-odc-ambitions | Added: 2026-03-27*
Blue Origin is attempting to replicate the SpaceX/Starlink vertical integration model with New Glenn + Project Sunrise (51,600 satellite ODC constellation). Manufacturing rate of 1 rocket/month with 12-24 launch target for 2026 shows serious infrastructure investment, but the gap between manufacturing capability and launch cadence (only 2 flights in 2025, NG-3 delayed as of March 2026) reveals that building the vertical integration infrastructure is insufficient—operational execution at scale is the binding constraint. Blue Origin is attempting to replicate the SpaceX/Starlink vertical integration model with New Glenn + Project Sunrise (51,600 satellite ODC constellation). Manufacturing rate of 1 rocket/month with 12-24 launch target for 2026 shows serious infrastructure investment, but the gap between manufacturing capability and launch cadence (only 2 flights in 2025, NG-3 delayed as of March 2026) reveals that building the vertical integration infrastructure is insufficient—operational execution at scale is the binding constraint.

2
domains/space-development/Starcloud is the first company to operate a datacenter-grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million-satellite constellation.md
View file

@ -59,4 +59,4 @@ Relevant Notes:
- [[SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal]] — SpaceX controls launch, networking, and is building a competing product - [[SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal]] — SpaceX controls launch, networking, and is building a competing product
Topics: Topics:
- [[space exploration and development]] - space exploration and development

2
domains/space-development/asteroid mining technology readiness drops sharply after prospecting with anchoring at TRL 2-3 and zero-gravity refining at TRL 1-2.md
View file

@ -40,4 +40,4 @@ Relevant Notes:
- [[microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors]] — microgravity is an advantage for manufacturing but a fundamental problem for mining - [[microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors]] — microgravity is an advantage for manufacturing but a fundamental problem for mining
Topics: Topics:
- [[space exploration and development]] - space exploration and development

16
domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md
View file

@ -30,44 +30,44 @@ The attractor state is a marketplace of orbital platforms serving manufacturing,
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-03-00-commercial-stations-haven1-slip-orbital-reef-delays]] | Added: 2026-03-19* *Source: 2026-03-00-commercial-stations-haven1-slip-orbital-reef-delays | Added: 2026-03-19*
Haven-1 has slipped from 2026 to 2027 (second delay), with first crewed mission now targeting summer 2027. Orbital Reef faces reported funding constraints at Blue Origin despite passing System Definition Review. Only Axiom remains on schedule with Hab One targeting 2026 ISS attachment. The ISS deorbit remains fixed at 2031, meaning the operational overlap window for knowledge transfer is compressing from 5+ years to potentially 4 years or less. This timeline slippage extends even to commercial programs with private capital, suggesting Pattern 2 (institutional timeline slippage) applies beyond government programs. Haven-1 has slipped from 2026 to 2027 (second delay), with first crewed mission now targeting summer 2027. Orbital Reef faces reported funding constraints at Blue Origin despite passing System Definition Review. Only Axiom remains on schedule with Hab One targeting 2026 ISS attachment. The ISS deorbit remains fixed at 2031, meaning the operational overlap window for knowledge transfer is compressing from 5+ years to potentially 4 years or less. This timeline slippage extends even to commercial programs with private capital, suggesting Pattern 2 (institutional timeline slippage) applies beyond government programs.
--- ---
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-01-21-haven1-delay-2027-manufacturing-pace]] | Added: 2026-03-21* *Source: 2026-01-21-haven1-delay-2027-manufacturing-pace | Added: 2026-03-21*
Haven-1, the first privately-funded commercial station attempt, has slipped 6 months (mid-2026 to Q1 2027) due to life support and thermal control integration pace. The delay is explicitly NOT launch-cost-related — Falcon 9 is available and affordable. This suggests the 'race to 2030' may be constrained more by technology maturation timelines than by capital or launch access, potentially widening the gap between first-mover aspirations and operational reality. Haven-1, the first privately-funded commercial station attempt, has slipped 6 months (mid-2026 to Q1 2027) due to life support and thermal control integration pace. The delay is explicitly NOT launch-cost-related — Falcon 9 is available and affordable. This suggests the 'race to 2030' may be constrained more by technology maturation timelines than by capital or launch access, potentially widening the gap between first-mover aspirations and operational reality.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-02-26-starlab-ccdr-full-scale-development]] | Added: 2026-03-21* *Source: 2026-02-26-starlab-ccdr-full-scale-development | Added: 2026-03-21*
Starlab completed Commercial Critical Design Review (CCDR) with NASA in February 2026, transitioning from design to full-scale development. This is the first commercial station program to reach CCDR milestone. Timeline: CDR expected late 2026, hardware fabrication 2026-2027, integration 2027-2028, single-flight Starship launch in 2028. The 2028 launch gives Starlab a 3-year operational window before ISS deorbits in 2031. Partnership consortium includes Voyager (prime, NYSE:VOYG), Airbus (inflatable habitat), Mitsubishi, MDA Space (robotics), Palantir (operations/data), Northrop Grumman (integration). Station designed for 12 simultaneous researchers. Development costs projected at $2.8-3.3B total, with $217.5M NASA Phase 1 funding and $15M Texas Space Commission funding. Critical constraint: NASA Phase 2 funding frozen as of January 28, 2026, creating funding gap of potentially $500M-$750M that private consortium must fill. Starlab completed Commercial Critical Design Review (CCDR) with NASA in February 2026, transitioning from design to full-scale development. This is the first commercial station program to reach CCDR milestone. Timeline: CDR expected late 2026, hardware fabrication 2026-2027, integration 2027-2028, single-flight Starship launch in 2028. The 2028 launch gives Starlab a 3-year operational window before ISS deorbits in 2031. Partnership consortium includes Voyager (prime, NYSE:VOYG), Airbus (inflatable habitat), Mitsubishi, MDA Space (robotics), Palantir (operations/data), Northrop Grumman (integration). Station designed for 12 simultaneous researchers. Development costs projected at $2.8-3.3B total, with $217.5M NASA Phase 1 funding and $15M Texas Space Commission funding. Critical constraint: NASA Phase 2 funding frozen as of January 28, 2026, creating funding gap of potentially $500M-$750M that private consortium must fill.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-02-12-nasa-vast-axiom-pam5-pam6-iss]] | Added: 2026-03-22* *Source: 2026-02-12-nasa-vast-axiom-pam5-pam6-iss | Added: 2026-03-22*
NASA awarded Axiom Mission 5 and Vast's first PAM in February 2026, demonstrating active government demand for commercial station services even before stations are operational. Vast's PAM award before Haven-1 launches shows NASA creating operational experience and revenue streams that reduce commercial station development risk. NASA awarded Axiom Mission 5 and Vast's first PAM in February 2026, demonstrating active government demand for commercial station services even before stations are operational. Vast's PAM award before Haven-1 launches shows NASA creating operational experience and revenue streams that reduce commercial station development risk.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-22-voyager-technologies-q4-fy2025-starlab-financials]] | Added: 2026-03-22* *Source: 2026-03-22-voyager-technologies-q4-fy2025-starlab-financials | Added: 2026-03-22*
Voyager Technologies completed Starlab's commercial Critical Design Review (CCDR) in 2025, marking 31 total milestones completed with $183.2M NASA cash received inception-to-date. The company maintains $704.7M liquidity (+15% sequential) specifically to bridge the design-to-manufacturing transition, demonstrating that commercial station developers are actively progressing through development gates with substantial capital reserves. Voyager Technologies completed Starlab's commercial Critical Design Review (CCDR) in 2025, marking 31 total milestones completed with $183.2M NASA cash received inception-to-date. The company maintains $704.7M liquidity (+15% sequential) specifically to bridge the design-to-manufacturing transition, demonstrating that commercial station developers are actively progressing through development gates with substantial capital reserves.
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-01-28-nasa-cld-phase2-frozen-saa-revised-approach]] | Added: 2026-03-23* *Source: 2026-01-28-nasa-cld-phase2-frozen-saa-revised-approach | Added: 2026-03-23*
NASA's January 28, 2026 Phase 2 CLD freeze placed the entire commercial station sector on hold indefinitely, and the July 2025 requirement reduction from 'permanently crewed' to 'crew-tended' suggests programs cannot meet the original operational bar. The freeze converts the 2030 timeline from a target to an open question, and the requirement softening reveals capability gaps that weren't visible in Phase 1 awards. NASA's January 28, 2026 Phase 2 CLD freeze placed the entire commercial station sector on hold indefinitely, and the July 2025 requirement reduction from 'permanently crewed' to 'crew-tended' suggests programs cannot meet the original operational bar. The freeze converts the 2030 timeline from a target to an open question, and the requirement softening reveals capability gaps that weren't visible in Phase 1 awards.
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-01-28-nasa-cld-phase2-frozen-saa-revised-approach]] | Added: 2026-03-24* *Source: 2026-01-28-nasa-cld-phase2-frozen-saa-revised-approach | Added: 2026-03-24*
NASA Phase 2 CLD program frozen January 28, 2026 with no replacement timeline, converting $1-1.5B anticipated funding into indefinite risk. Requirements previously softened from 'permanently crewed' to 'crew-tended' in July 2025, suggesting original operational bar was unachievable. Phil McAlister characterized freeze as 'schedule risk' not 'safety risk,' implying programs can wait but cannot proceed without NASA anchor funding. NASA Phase 2 CLD program frozen January 28, 2026 with no replacement timeline, converting $1-1.5B anticipated funding into indefinite risk. Requirements previously softened from 'permanently crewed' to 'crew-tended' in July 2025, suggesting original operational bar was unachievable. Phil McAlister characterized freeze as 'schedule risk' not 'safety risk,' implying programs can wait but cannot proceed without NASA anchor funding.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-27-nasa-authorization-act-iss-overlap-mandate]] | Added: 2026-03-27* *Source: 2026-03-27-nasa-authorization-act-iss-overlap-mandate | Added: 2026-03-27*
The NASA Authorization Act of 2026 overlap mandate creates a policy-engineered Gate 2 by requiring ISS to operate alongside a fully operational commercial station for one year with 180 days of concurrent crew operations. This transforms the 'void' from a market opportunity into a mandated transition condition with specific technical requirements and government anchor tenant guarantees. The NASA Authorization Act of 2026 overlap mandate creates a policy-engineered Gate 2 by requiring ISS to operate alongside a fully operational commercial station for one year with 180 days of concurrent crew operations. This transforms the 'void' from a market opportunity into a mandated transition condition with specific technical requirements and government anchor tenant guarantees.

14
domains/space-development/falling launch costs paradoxically both enable and threaten in-space resource utilization by making infrastructure affordable while competing with the end product.md
View file

@ -28,43 +28,43 @@ The investment implication is that ISRU businesses should be evaluated not again
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-18-interlune-doe-helium3-purchase]] | Added: 2026-03-18* *Source: 2026-03-18-interlune-doe-helium3-purchase | Added: 2026-03-18*
Helium-3 extraction avoids the launch cost competition problem that threatens water-for-propellant economics because helium-3's terrestrial scarcity and quantum computing demand create a market where lunar extraction competes against constrained Earth supply rather than against launch services. This suggests resources with high Earth-side value and limited terrestrial supply may be more economically viable than resources primarily valuable for in-space use. Helium-3 extraction avoids the launch cost competition problem that threatens water-for-propellant economics because helium-3's terrestrial scarcity and quantum computing demand create a market where lunar extraction competes against constrained Earth supply rather than against launch services. This suggests resources with high Earth-side value and limited terrestrial supply may be more economically viable than resources primarily valuable for in-space use.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-18-spacenews-lunar-economy-resources-reactors]] | Added: 2026-03-18* *Source: 2026-03-18-spacenews-lunar-economy-resources-reactors | Added: 2026-03-18*
The helium-3 quantum computing demand creates a case where lunar resources have Earth-side markets that launch cost reductions cannot compete with, because the resource literally doesn't exist on Earth in sufficient quantities. This represents a boundary condition where the paradox doesn't apply: when the resource is unavailable terrestrially, launch costs only affect the extraction economics, not the market viability. The helium-3 quantum computing demand creates a case where lunar resources have Earth-side markets that launch cost reductions cannot compete with, because the resource literally doesn't exist on Earth in sufficient quantities. This represents a boundary condition where the paradox doesn't apply: when the resource is unavailable terrestrially, launch costs only affect the extraction economics, not the market viability.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-18-interlune-afwerx-terrestrial-he3-extraction]] | Added: 2026-03-18* *Source: 2026-03-18-interlune-afwerx-terrestrial-he3-extraction | Added: 2026-03-18*
Interlune is developing terrestrial helium-3 extraction via cryogenic distillation from natural helium gas streams under a $1.25M AFWERX contract. This represents a direct terrestrial supply alternative to lunar He-3, not just cheaper launch competing with space resources. The He-3 concentration in natural helium (~0.0001% He-3/He-4 ratio) limits terrestrial scale, but proves the extraction technology works and creates a dual-use hedge for Interlune's lunar thesis. Interlune is developing terrestrial helium-3 extraction via cryogenic distillation from natural helium gas streams under a $1.25M AFWERX contract. This represents a direct terrestrial supply alternative to lunar He-3, not just cheaper launch competing with space resources. The He-3 concentration in natural helium (~0.0001% He-3/He-4 ratio) limits terrestrial scale, but proves the extraction technology works and creates a dual-use hedge for Interlune's lunar thesis.
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-03-18-interlune-afwerx-terrestrial-he3-extraction]] | Added: 2026-03-18* *Source: 2026-03-18-interlune-afwerx-terrestrial-he3-extraction | Added: 2026-03-18*
Interlune's terrestrial He-3 extraction program suggests the threat to lunar resource economics may come from improved terrestrial extraction technology rather than just cheaper launch. If cryogenic distillation becomes economical at scale, the scarcity premium driving lunar He-3 prices could collapse before lunar infrastructure is built. This is a supply-side substitution risk, not a launch cost arbitrage. Interlune's terrestrial He-3 extraction program suggests the threat to lunar resource economics may come from improved terrestrial extraction technology rather than just cheaper launch. If cryogenic distillation becomes economical at scale, the scarcity premium driving lunar He-3 prices could collapse before lunar infrastructure is built. This is a supply-side substitution risk, not a launch cost arbitrage.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-02-00-euca2al9-china-nature-adr-he3-replacement]] | Added: 2026-03-19* *Source: 2026-02-00-euca2al9-china-nature-adr-he3-replacement | Added: 2026-03-19*
EuCo2Al9 ADR materials create a terrestrial alternative to lunar He-3 extraction, demonstrating the substitution risk pattern at the materials level. If rare-earth ADR can achieve qubit-temperature cooling without He-3, it eliminates the quantum computing demand driver for lunar He-3 mining before space infrastructure costs fall enough to make extraction economical. This extends the launch cost paradox from 'cheap launch competes with space resources' to 'terrestrial material substitution races against space infrastructure deployment.' EuCo2Al9 ADR materials create a terrestrial alternative to lunar He-3 extraction, demonstrating the substitution risk pattern at the materials level. If rare-earth ADR can achieve qubit-temperature cooling without He-3, it eliminates the quantum computing demand driver for lunar He-3 mining before space infrastructure costs fall enough to make extraction economical. This extends the launch cost paradox from 'cheap launch competes with space resources' to 'terrestrial material substitution races against space infrastructure deployment.'
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-01-29-interlune-5m-safe-500m-contracts-2026-milestones]] | Added: 2026-03-19* *Source: 2026-01-29-interlune-5m-safe-500m-contracts-2026-milestones | Added: 2026-03-19*
Interlune's milestone-gated financing structure suggests investors are managing the 'launch cost competition' risk by deferring capital deployment until technology proves out. The $23M raised vs. $500M+ contracts ratio shows investors won't fund full-scale infrastructure until extraction is demonstrated, precisely because falling launch costs create uncertainty about whether lunar He-3 can compete with terrestrial alternatives or Earth-launched supplies. Interlune's milestone-gated financing structure suggests investors are managing the 'launch cost competition' risk by deferring capital deployment until technology proves out. The $23M raised vs. $500M+ contracts ratio shows investors won't fund full-scale infrastructure until extraction is demonstrated, precisely because falling launch costs create uncertainty about whether lunar He-3 can compete with terrestrial alternatives or Earth-launched supplies.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2025-07-30-jacs-kyb3f10-adr-27mK-helium-free]] | Added: 2026-03-20* *Source: 2025-07-30-jacs-kyb3f10-adr-27mK-helium-free | Added: 2026-03-20*
ADR systems using frustrated magnets (KYb3F10) achieved 27.2 mK in July 2025, approaching superconducting qubit temperatures and demonstrating that He-3 substitution technology is advancing faster than previously assumed. The gap between research ADR (27.2 mK) and qubit requirements (10-15 mK) is now only ~2x, compared to commercial ADR at 100-300 mK (4-10x gap). This accelerates the substitution timeline for He-3 demand in quantum computing, the primary terrestrial application driving cislunar He-3 extraction economics. ADR systems using frustrated magnets (KYb3F10) achieved 27.2 mK in July 2025, approaching superconducting qubit temperatures and demonstrating that He-3 substitution technology is advancing faster than previously assumed. The gap between research ADR (27.2 mK) and qubit requirements (10-15 mK) is now only ~2x, compared to commercial ADR at 100-300 mK (4-10x gap). This accelerates the substitution timeline for He-3 demand in quantum computing, the primary terrestrial application driving cislunar He-3 extraction economics.

8
domains/space-development/launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds.md
View file

@ -33,17 +33,17 @@ The keystone variable framing implies a single bottleneck, but space development
--- ---
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-01-21-haven1-delay-2027-manufacturing-pace]] | Added: 2026-03-21* *Source: 2026-01-21-haven1-delay-2027-manufacturing-pace | Added: 2026-03-21*
Haven-1's delay provides a boundary condition: once launch cost crosses below a threshold (~$67M for Falcon 9), the binding constraint shifts to technology development pace (life support integration, avionics, thermal control). For commercial stations in 2026, launch cost is no longer the keystone variable — it has been solved. The new keystone is knowledge embodiment in complex habitation systems. Haven-1's delay provides a boundary condition: once launch cost crosses below a threshold (~$67M for Falcon 9), the binding constraint shifts to technology development pace (life support integration, avionics, thermal control). For commercial stations in 2026, launch cost is no longer the keystone variable — it has been solved. The new keystone is knowledge embodiment in complex habitation systems.
### Additional Evidence (confirm) ### Additional Evidence (confirm)
*Source: [[2026-03-27-starship-falcon9-cost-2026-commercial-operations]] | Added: 2026-03-27* *Source: 2026-03-27-starship-falcon9-cost-2026-commercial-operations | Added: 2026-03-27*
As of March 2026, Starship operational cost is $1,600/kg, creating an 8x gap to the $200/kg ODC threshold. No commercial ODC operations have materialized despite technical readiness, consistent with the thesis that specific cost thresholds gate sector emergence. As of March 2026, Starship operational cost is $1,600/kg, creating an 8x gap to the $200/kg ODC threshold. No commercial ODC operations have materialized despite technical readiness, consistent with the thesis that specific cost thresholds gate sector emergence.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-28-keeptrack-starship-v3-april-2026]] | Added: 2026-03-28* *Source: 2026-03-28-keeptrack-starship-v3-april-2026 | Added: 2026-03-28*
The gap between Starship entering commercial service (2027 with Superbird-9) and clearing specific price thresholds creates a multi-year lag between launch availability and sector activation. Current $1,600/kg operational cost vs. $200/kg ODC threshold demonstrates that vehicle availability does not equal threshold crossing—the cost reduction curve has its own timeline independent of commercial service debut. The gap between Starship entering commercial service (2027 with Superbird-9) and clearing specific price thresholds creates a multi-year lag between launch availability and sector activation. Current $1,600/kg operational cost vs. $200/kg ODC threshold demonstrates that vehicle availability does not equal threshold crossing—the cost reduction curve has its own timeline independent of commercial service debut.
@ -56,4 +56,4 @@ Relevant Notes:
- [[the space launch cost trajectory is a phase transition not a gradual decline analogous to sail-to-steam in maritime transport]] — the framing for why this is discontinuous structural change - [[the space launch cost trajectory is a phase transition not a gradual decline analogous to sail-to-steam in maritime transport]] — the framing for why this is discontinuous structural change
Topics: Topics:
- [[space exploration and development]] - space exploration and development

2
domains/space-development/orbital data centers are the most speculative near-term space application but the convergence of AI compute demand and falling launch costs attracts serious players.md
View file

@ -52,4 +52,4 @@ Relevant Notes:
- [[Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy]] — orbital data centers require Starship-era launch costs - [[Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy]] — orbital data centers require Starship-era launch costs
Topics: Topics:
- [[space exploration and development]] - space exploration and development

2
domains/space-development/orbital data centers require five enabling technologies to mature simultaneously and none currently exist at required readiness.md
View file

@ -49,4 +49,4 @@ Relevant Notes:
- [[modern AI accelerators are more radiation-tolerant than expected because Google TPU testing showed no hard failures up to 15 krad suggesting consumer chips may survive LEO environments]] — technology #4 showing promising early results - [[modern AI accelerators are more radiation-tolerant than expected because Google TPU testing showed no hard failures up to 15 krad suggesting consumer chips may survive LEO environments]] — technology #4 showing promising early results
Topics: Topics:
- [[space exploration and development]] - space exploration and development

10
domains/space-development/reusability without rapid turnaround and minimal refurbishment does not reduce launch costs as the Space Shuttle proved over 30 years.md
View file

@ -25,30 +25,30 @@ SpaceX's Falcon 9 demonstrated the correct approach with booster recovery requir
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-18-blue-origin-ng3-booster-reuse]] | Added: 2026-03-18* *Source: 2026-03-18-blue-origin-ng3-booster-reuse | Added: 2026-03-18*
Blue Origin's New Glenn booster achieved ~3 month turnaround for first reuse attempt (NG-2 Nov 2025 to NG-3 late Feb 2026), with booster designed for 25+ flights. This represents a significantly faster turnaround than Space Shuttle's multi-month refurbishment cycles, suggesting Blue Origin learned from Shuttle's operational failures. Blue Origin's New Glenn booster achieved ~3 month turnaround for first reuse attempt (NG-2 Nov 2025 to NG-3 late Feb 2026), with booster designed for 25+ flights. This represents a significantly faster turnaround than Space Shuttle's multi-month refurbishment cycles, suggesting Blue Origin learned from Shuttle's operational failures.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-18-new-glenn-ng3-booster-reuse-pending]] | Added: 2026-03-18* *Source: 2026-03-18-new-glenn-ng3-booster-reuse-pending | Added: 2026-03-18*
Blue Origin's New Glenn NG-3 mission demonstrates a ~3-month booster turnaround time (Nov 2025 landing to March 2026 relaunch). This is slower than SpaceX's best (<30 days) but faster than early Falcon 9 reuse cycles, providing a new data point on the turnaround spectrum between Space Shuttle (months of refurbishment) and mature SpaceX operations. Blue Origin's New Glenn NG-3 mission demonstrates a ~3-month booster turnaround time (Nov 2025 landing to March 2026 relaunch). This is slower than SpaceX's best (<30 days) but faster than early Falcon 9 reuse cycles, providing a new data point on the turnaround spectrum between Space Shuttle (months of refurbishment) and mature SpaceX operations.
--- ---
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-19-spacex-starship-b19-partial-static-fire-10-engines]] | Added: 2026-03-25* *Source: 2026-03-19-spacex-starship-b19-partial-static-fire-10-engines | Added: 2026-03-25*
V3 qualification timeline shows the challenge of validating new engine generations at scale. The 10-engine partial static fire (March 16) to 33-engine full static fire sequence demonstrates that even with successful engine startup, ground systems integration (GSE at new Pad 2) creates qualification bottlenecks. Each delay in V3 validation extends the timeline to operational reusability with Raptor 3. V3 qualification timeline shows the challenge of validating new engine generations at scale. The 10-engine partial static fire (March 16) to 33-engine full static fire sequence demonstrates that even with successful engine startup, ground systems integration (GSE at new Pad 2) creates qualification bottlenecks. Each delay in V3 validation extends the timeline to operational reusability with Raptor 3.
### Additional Evidence (confirm) ### Additional Evidence (confirm)
*Source: [[2026-03-27-blueorigin-new-glenn-manufacturing-odc-ambitions]] | Added: 2026-03-27* *Source: 2026-03-27-blueorigin-new-glenn-manufacturing-odc-ambitions | Added: 2026-03-27*
Blue Origin's New Glenn program shows manufacturing rate (1/month) significantly exceeding launch cadence (2 total launches in 2025), with NG-3 still delayed as of March 2026. This demonstrates that building reusable hardware does not automatically translate to high-cadence operations—the operational knowledge (pad turnaround, refurbishment processes, flight software maturity) lags behind manufacturing capability. Blue Origin's New Glenn program shows manufacturing rate (1/month) significantly exceeding launch cadence (2 total launches in 2025), with NG-3 still delayed as of March 2026. This demonstrates that building reusable hardware does not automatically translate to high-cadence operations—the operational knowledge (pad turnaround, refurbishment processes, flight software maturity) lags behind manufacturing capability.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-28-nasaspaceflight-new-glenn-manufacturing-odc-ambitions]] | Added: 2026-03-28* *Source: 2026-03-28-nasaspaceflight-new-glenn-manufacturing-odc-ambitions | Added: 2026-03-28*
New Glenn NG-3 mission will attempt first booster reuse (reflying 'Never Tell Me The Odds' from NG-1), but the 15-month gap between NG-1 and NG-3 demonstrates that achieving reuse is separate from achieving rapid reuse. Even with a reusable booster available since January 2025, operational tempo remains the binding constraint on cost reduction through reuse economics. New Glenn NG-3 mission will attempt first booster reuse (reflying 'Never Tell Me The Odds' from NG-1), but the 15-month gap between NG-1 and NG-3 demonstrates that achieving reuse is separate from achieving rapid reuse. Even with a reusable booster available since January 2025, operational tempo remains the binding constraint on cost reduction through reuse economics.

6
domains/space-development/reusable-launch-convergence-creates-us-china-duopoly-in-heavy-lift.md
View file

@ -38,19 +38,19 @@ This is a snapshot of March 2026 program status, not a permanent structural cond
### Additional Evidence (challenge) ### Additional Evidence (challenge)
*Source: [[2026-02-11-china-long-march-10-sea-landing]] | Added: 2026-03-16* *Source: 2026-02-11-china-long-march-10-sea-landing | Added: 2026-03-16*
China demonstrated controlled first-stage sea landing on February 11, 2026, with Long March 10B reusable variant launching April 5, 2026. The reusability gap closed in ~2 years, not the 5-8 years previously estimated. This suggests state-directed industrial policy accelerates technology development faster than market-driven timelines predicted. China demonstrated controlled first-stage sea landing on February 11, 2026, with Long March 10B reusable variant launching April 5, 2026. The reusability gap closed in ~2 years, not the 5-8 years previously estimated. This suggests state-directed industrial policy accelerates technology development faster than market-driven timelines predicted.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-02-11-china-long-march-10-sea-landing]] | Added: 2026-03-16* *Source: 2026-02-11-china-long-march-10-sea-landing | Added: 2026-03-16*
China's recovery approach uses tethered wire/cable-net systems fundamentally different from SpaceX's tower catch or ship landing, demonstrating independent innovation trajectory rather than pure technology copying. The 25,000-ton 'Ling Hang Zhe' recovery ship with specialized cable gantry represents a distinct engineering solution optimized for sea-based operations. China's recovery approach uses tethered wire/cable-net systems fundamentally different from SpaceX's tower catch or ship landing, demonstrating independent innovation trajectory rather than pure technology copying. The 25,000-ton 'Ling Hang Zhe' recovery ship with specialized cable gantry represents a distinct engineering solution optimized for sea-based operations.
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-03-18-starship-flight12-v3-status]] | Added: 2026-03-18* *Source: 2026-03-18-starship-flight12-v3-status | Added: 2026-03-18*
While competitors close the reusability gap (per 2026-03-11 findings), V3 widens the capability gap through 3x payload increase. This creates a two-dimensional competition space where reusability becomes table stakes but payload capacity determines strategic positioning. V3 at 100+ tonnes LEO moves Starship into a capability tier no competitor has announced plans to reach. While competitors close the reusability gap (per 2026-03-11 findings), V3 widens the capability gap through 3x payload increase. This creates a two-dimensional competition space where reusability becomes table stakes but payload capacity determines strategic positioning. V3 at 100+ tonnes LEO moves Starship into a capability tier no competitor has announced plans to reach.

2
domains/space-development/space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density.md
View file

@ -45,4 +45,4 @@ Relevant Notes:
- [[distributed LEO inference networks could serve global AI requests at 4-20ms latency competitive with centralized terrestrial data centers for latency-tolerant workloads]] — the viable long-term use case - [[distributed LEO inference networks could serve global AI requests at 4-20ms latency competitive with centralized terrestrial data centers for latency-tolerant workloads]] — the viable long-term use case
Topics: Topics:
- [[space exploration and development]] - space exploration and development

2
domains/space-development/space-based pharmaceutical manufacturing produces clinically superior drug formulations that cannot be replicated on Earth.md
View file

@ -42,4 +42,4 @@ Relevant Notes:
- [[microgravity-discovered pharmaceutical polymorphs are a novel IP mechanism because new crystal forms enable patent extension reformulation and new delivery methods]] — the specific IP mechanism - [[microgravity-discovered pharmaceutical polymorphs are a novel IP mechanism because new crystal forms enable patent extension reformulation and new delivery methods]] — the specific IP mechanism
Topics: Topics:
- [[space exploration and development]] - space exploration and development

2
domains/space-development/ten percent of near-Earth asteroids are more energetically accessible than the lunar surface with some requiring less delta-v than a soft Moon landing.md
View file

@ -38,4 +38,4 @@ Relevant Notes:
- [[the Moon serves as a proving ground for Mars settlement because 2-day transit enables 180x faster iteration cycles than the 6-month Mars journey]] — lunar proximity advantage offsets asteroid energy advantage for development iteration - [[the Moon serves as a proving ground for Mars settlement because 2-day transit enables 180x faster iteration cycles than the 6-month Mars journey]] — lunar proximity advantage offsets asteroid energy advantage for development iteration
Topics: Topics:
- [[space exploration and development]] - space exploration and development

2
domains/space-development/the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit.md
View file

@ -37,4 +37,4 @@ Relevant Notes:
- [[Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors]] — Axiom's financial instability is the single largest risk factor - [[Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors]] — Axiom's financial instability is the single largest risk factor
Topics: Topics:
- [[space exploration and development]] - space exploration and development

6
domains/space-development/the space launch cost trajectory is a phase transition not a gradual decline analogous to sail-to-steam in maritime transport.md
View file

@ -31,20 +31,20 @@ Phase transition framing implies inevitability, but the transition requires sust
### Additional Evidence (confirm) ### Additional Evidence (confirm)
*Source: [[2026-03-00-phys-org-europe-answer-to-starship]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5* *Source: 2026-03-00-phys-org-europe-answer-to-starship | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
Europe's institutional response to the reusability revolution demonstrates the phase-transition nature of the shift. The German Aerospace Center's assessment that "Europe is toast without a Starship clone" frames this as a binary strategic divide, not a gradual improvement curve. Europe has three separate reusable launch concepts under development (RLV C5, SUSIE, ESA/Avio), yet all remain in early design phase with no operational timelines as of March 2026. Meanwhile, Ariane 6—which first flew in 2024 as an expendable vehicle—is already assessed as strategically obsolete by Europe's own institutions. This is not a case of Europe being slightly behind on a continuous improvement trajectory; it's a recognition that the competitive structure has fundamentally changed and incremental improvements won't close the gap. The fact that SUSIE is explicitly characterized as "catching up with current US capabilities, not competing with next-gen" reinforces that this is a discrete phase transition where being in the wrong era creates strategic irrelevance. Europe's institutional response to the reusability revolution demonstrates the phase-transition nature of the shift. The German Aerospace Center's assessment that "Europe is toast without a Starship clone" frames this as a binary strategic divide, not a gradual improvement curve. Europe has three separate reusable launch concepts under development (RLV C5, SUSIE, ESA/Avio), yet all remain in early design phase with no operational timelines as of March 2026. Meanwhile, Ariane 6—which first flew in 2024 as an expendable vehicle—is already assessed as strategically obsolete by Europe's own institutions. This is not a case of Europe being slightly behind on a continuous improvement trajectory; it's a recognition that the competitive structure has fundamentally changed and incremental improvements won't close the gap. The fact that SUSIE is explicitly characterized as "catching up with current US capabilities, not competing with next-gen" reinforces that this is a discrete phase transition where being in the wrong era creates strategic irrelevance.
### Additional Evidence (confirm) ### Additional Evidence (confirm)
*Source: [[2026-03-18-starship-flight12-v3-status]] | Added: 2026-03-18* *Source: 2026-03-18-starship-flight12-v3-status | Added: 2026-03-18*
V3's 3x payload jump from V2 (35t to 100+ tonnes) within a single vehicle generation exemplifies discontinuous capability improvement characteristic of phase transitions. The 30-minute propellant loading time for B19 and accumulated 40,000+ seconds of Raptor 3 testing show operational maturation accelerating alongside performance gains, compressing the transition timeline. V3's 3x payload jump from V2 (35t to 100+ tonnes) within a single vehicle generation exemplifies discontinuous capability improvement characteristic of phase transitions. The 30-minute propellant loading time for B19 and accumulated 40,000+ seconds of Raptor 3 testing show operational maturation accelerating alongside performance gains, compressing the transition timeline.
--- ---
### Additional Evidence (extend) ### Additional Evidence (extend)
*Source: [[2026-xx-richmondfed-rural-electrification-two-gate-analogue]] | Added: 2026-03-24* *Source: 2026-xx-richmondfed-rural-electrification-two-gate-analogue | Added: 2026-03-24*
Rural electrification provides a second phase-transition analogue: supply threshold crossed quietly in the 1910s-1920s (urban electrification), demand threshold crossed suddenly with REA catalyst in 1936, then rapid adoption (400 miles of REA lines in 1936 → 115,230 miles by 1939). The transition pattern is supply readiness + catalytic intervention + rapid scaling, not gradual linear adoption. Rural electrification provides a second phase-transition analogue: supply threshold crossed quietly in the 1910s-1920s (urban electrification), demand threshold crossed suddenly with REA catalyst in 1936, then rapid adoption (400 miles of REA lines in 1936 → 115,230 miles by 1939). The transition pattern is supply readiness + catalytic intervention + rapid scaling, not gradual linear adoption.

2
domains/space-development/varda-space-biologics-development-blurs-three-tier-manufacturing-sequence.md
View file

@ -41,4 +41,4 @@ Relevant Notes:
- [[microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors]] <!-- claim pending --> - [[microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors]] <!-- claim pending -->
Topics: Topics:
- [[domains/space-development/_map]] - domains/space-development/_map

4
domains/space-development/varda-vertical-integration-reduces-space-manufacturing-access-costs.md
View file

@ -33,7 +33,7 @@ This claim infers cost reduction from vertical integration and cadence accelerat
### Additional Evidence (confirm) ### Additional Evidence (confirm)
*Source: [[2026-03-18-varda-w5-vertically-integrated-bus]] | Added: 2026-03-18* *Source: 2026-03-18-varda-w5-vertically-integrated-bus | Added: 2026-03-18*
Varda W-5 mission (January 2026) successfully deployed first vertically integrated satellite bus and in-house manufactured C-PICA heatshield, completing full mission lifecycle control. This is the 5th mission (4 in 2025 alone), demonstrating the vertical integration thesis is now operational at scale, not theoretical. Varda W-5 mission (January 2026) successfully deployed first vertically integrated satellite bus and in-house manufactured C-PICA heatshield, completing full mission lifecycle control. This is the 5th mission (4 in 2025 alone), demonstrating the vertical integration thesis is now operational at scale, not theoretical.
@ -44,4 +44,4 @@ Relevant Notes:
- [[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]] - [[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]
Topics: Topics:
- [[domains/space-development/_map]] - domains/space-development/_map